Half-year report · Q2
8086.TEDINET S100UQIB
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥312.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥586.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥285.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥13.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥13.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥19.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥14.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥17.5bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥129m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥813m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥10.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.17T | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥1.11T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.10T | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥875.4bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥840.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥298.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥269.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥274.0bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥92.6bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥99.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥85.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥96.6bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥83.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥84.7bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥15.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥72.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥18.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥54.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥87.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥35.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥23.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥22.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥8.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥0.79 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.12 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.89 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥0.7 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥60.35 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥53.95 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 22.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥383m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥272m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥14.9bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥245.6bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥242.1bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥24.5bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥68.4bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥38.0bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥30.4bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥31.6bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥931m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥348.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥311.6bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥37.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥351.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥312.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥39.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥417m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥109m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥36.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥36.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥14.1bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥223.6bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥220.2bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥22.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥62.9bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥35.2bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥27.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥33.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥30.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥319.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥285.4bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥34.0bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥27.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥321.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥285.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥36.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥27.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 641
| Item | Context | Value | Unit |
|---|---|---|---|
| Other ca | CurrentQuarterInstant | 55588000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -5362000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -6350000000 | JPY |
| Current assets | Prior1YearInstant | 524166000000 | JPY |
| Current assets | CurrentQuarterInstant | 564656000000 | JPY |
| Buildings and structures | Prior1YearInstant | 337409000000 | JPY |
| Buildings and structures | CurrentQuarterInstant | 349216000000 | JPY |
| Accumulated depreciation and impairment loss buildings and structures | Prior1YearInstant | -156680000000 | JPY |
| Accumulated depreciation and impairment loss buildings and structures | CurrentQuarterInstant | -166359000000 | JPY |
| Buildings and structures net | Prior1YearInstant | 180729000000 | JPY |
| Buildings and structures net | CurrentQuarterInstant | 182856000000 | JPY |
| Machinery equipment and vehicles | Prior1YearInstant | 408015000000 | JPY |
| Machinery equipment and vehicles | CurrentQuarterInstant | 445474000000 | JPY |
| Accumulated depreciation and impairment loss machinery equipment and vehicles | Prior1YearInstant | -288780000000 | JPY |
| Accumulated depreciation and impairment loss machinery equipment and vehicles | CurrentQuarterInstant | -311442000000 | JPY |
| Machinery equipment and vehicles net | Prior1YearInstant | 119235000000 | JPY |
| Machinery equipment and vehicles net | CurrentQuarterInstant | 134032000000 | JPY |
| Land | Prior1YearInstant | 47061000000 | JPY |
| Land | CurrentQuarterInstant | 47790000000 | JPY |
| Lease assets ppe | Prior1YearInstant | 40149000000 | JPY |
| Lease assets ppe | CurrentQuarterInstant | 42600000000 | JPY |
| Accumulated depreciation lease assets ppe | Prior1YearInstant | -16778000000 | JPY |
| Accumulated depreciation lease assets ppe | CurrentQuarterInstant | -18803000000 | JPY |
| Lease assets net ppe | Prior1YearInstant | 23371000000 | JPY |
| Lease assets net ppe | CurrentQuarterInstant | 23796000000 | JPY |
| Construction in progress | Prior1YearInstant | 83284000000 | JPY |
| Construction in progress | CurrentQuarterInstant | 86320000000 | JPY |
| Other ppe | Prior1YearInstant | 101983000000 | JPY |
| Other ppe | CurrentQuarterInstant | 110915000000 | JPY |
| Accumulated depreciation and impairment loss other ppe | Prior1YearInstant | -74156000000 | JPY |
| Accumulated depreciation and impairment loss other ppe | CurrentQuarterInstant | -80823000000 | JPY |
| Other net ppe | Prior1YearInstant | 27826000000 | JPY |
| Other net ppe | CurrentQuarterInstant | 30091000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 481508000000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 504888000000 | JPY |
| Goodwill | Prior1YearInstant | 15607000000 | JPY |
| Goodwill | CurrentQuarterInstant | 16528000000 | JPY |
| Lease assets ia | Prior1YearInstant | 1921000000 | JPY |
| Lease assets ia | CurrentQuarterInstant | 2153000000 | JPY |
| Other ia | Prior1YearInstant | 17609000000 | JPY |
| Other ia | CurrentQuarterInstant | 19095000000 | JPY |
| Intangible assets | Prior1YearInstant | 35138000000 | JPY |
| Intangible assets | CurrentQuarterInstant | 37777000000 | JPY |
| Investment securities | Prior1YearInstant | 32945000000 | JPY |
| Investment securities | CurrentQuarterInstant | 30177000000 | JPY |
| Net defined benefit asset | Prior1YearInstant | 94000000 | JPY |
| Net defined benefit asset | CurrentQuarterInstant | 268000000 | JPY |
| Deferred tax assets | Prior1YearInstant | 13116000000 | JPY |
| Deferred tax assets | CurrentQuarterInstant | 13797000000 | JPY |
| Other ioa | Prior1YearInstant | 29990000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |